se of Analgesics in the treatment of Oral Sub Mucous Fibrosis
- Conditions
- Health Condition 1: K135- Oral submucous fibrosisHealth Condition 2: K135- Oral submucous fibrosis
- Registration Number
- CTRI/2022/03/041108
- Lead Sponsor
- Applied for intramural grant RIMS Ranchi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Consecutive patients with clinically suspected OSMF will be considered for the study.
2. Patients with current or previous use of any form of smokeless tobacco and/or areca nut (any duration and frequency)
3. Patients having late-stage OSMF designated as Grade III and IV by the grading system proposed by Kerr et al.
4. Patients willing to quit the habit of smokeless tobacco and/or areca nut.
5. Patients willing to accept regular follow-up protocol
6. Histopathological confirmation of OSMF by incisional biopsy
1.Patients having early-stage OSMF designated as Grade I and II by the grading system proposed by Kerr et al.
2.Patients with known allergy or contra-indication to COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides.
3.Patients having diagnosis or treatment of esophageal, gastric, pyloric channel, or duodenal ulceration within past 30 days, prior or active pancreatic disease or inflammatory bowel disease or Hemophilia or a history of bleeding disorders or Gout or a history of gout
4.Patients already undergoing treatment for OSMF.
5.Pregnant and lactating females.
6.Patients having concomitant pericoronitis or any other dental condition leading to trismus.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method